Hormonal Changes After Laparoscopic Ovarian Diathermy in Patients with Polycystic Ovarian Syndrome

被引：1
作者：
Elnaggar E.A. [1 ]
Elwan Y.A. [1 ]
Ibrahim S.A. [1 ]
Abdalla M.M. [2 ]
机构：
[1] Department of Obstetrics and Gynecology, Zagazig University Hospital, Zagazig
[2] Department of Obstetrics and Gynecology, Menia Health Insurance Hospital, El Ménia
来源：
The Journal of Obstetrics and Gynecology of India | 2016年 / 66卷 / Suppl 1期
关键词：
Hormonal changes; Infertility; Laparoscopic ovarian drilling; Laparoscopy; Polycystic ovarian syndrome;
D O I：
10.1007/s13224-016-0882-2
中图分类号：
学科分类号：
摘要：
Aim of the present study: To assess the changes in hormonal profile (serum FSH, LH, prolactin and total testosterone) following laparoscopic ovarian drilling (LOD) in patients with polycystic ovarian syndrome. Materials and methods: Fifty patients with PCOS have been included in this study. Serum prolactin, total testosterone, follicular-stimulating hormone (FSH) and luteinizing hormone (LH) levels have been used as biochemical markers, before and after procedures. Results: Laparoscopic ovarian drilling was successfully employed without any surgical complications and on an average follow-up time of 24 weeks after the procedure. During the follow-up serum values for prolactin, total testosterone and LH have decreased significantly and FSH levels remained unchanged after the procedure. Conclusions: The LOD in patients with PCOS may avoid or reduce the risk of OHSS and the multiple pregnancy rate induced by gonadotropin therapy. The high pregnancy rate and the economic aspect of the procedure offer an attractive management for patients with PCOS. However, LOD can be considered as second-line treatment after clomiphene citrate treatment failure and/or resistance. © 2016, Federation of Obstetric & Gynecological Societies of India.
引用
收藏
页码：528 / 533
页数：5
相关论文
共 33 条
  • [1] Goodarzi M.O., Dumesic D.A., Chazenbalk G., Et al., Polycyctic ovary syndrome: etiology, pathogenesis and diagnosis, Nat Rev Endocrinol, 7, pp. 219-231, (2011)
  • [2] Fauser B., Tarlatz B., Chang J., The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long term health risks related to polycystic ovary syndrome, Hum Reprod, 19, pp. 41-47, (2004)
  • [3] Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome, Fertil Steril, 81, pp. 19-25, (2003)
  • [4] Consensus on infertility treatment related to polycystic ovary syndrome, Fertil Steril, 89, 3, pp. 505-522, (2008)
  • [5] Consensus on women’s health aspects of polycystic ovary syndrome (PCOS), Hum Reprod, 27, 1, pp. 14-24, (2012)
  • [6] Franik S., Kremer J.A., Nelen W.L., Et al., Aromatase inhibitors for subfertile women with polycystic ovary syndrome: summary of a Cochrane review, Fertil Steril, 103, 2, pp. 353-355, (2015)
  • [7] Legro R.S., Brzyski R.G., Diamond M.P., Et al., Letrozole versus clomiphene for infertility in the polycystic ovary syndrome, N Engl J Med, 371, 2, pp. 119-129, (2014)
  • [8] Panidis D., Tziomalos K., Papadakis E., Et al., The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration, Horm (Athens), 12, 2, pp. 192-200, (2013)
  • [9] Ayaz A., Alwan Y., Farooq M.U., Efficacy of combined metformin-clomiphene citrate in comparison with clomiphene citrate alone in infertile women with polycystic ovarian syndrome (PCOS), J Med Life, 6, 2, pp. 199-201, (2013)
  • [10] Tso L.O., Costello M.F., Albuquerque L.E., Et al., Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome, Cochrane Database Syst Rev, 11, (2014)
1234